Effect Of Lactobacillus GG on Atopic March

Cow's Milk Allergy Clinical Trial

Official title:

Preventive Effect of Lactobacillus GG on Atopic Manifestation in Children With Cow's Milk Allergy

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01891916
• Other study ID #: 109/11
• Status: Recruiting
• Phase: N/A
• First received: June 28, 2013
• Last updated: July 15, 2013
• Start date: October 2008
• Est. completion date: December 2014

Study information

• Verified date: July 2013
• Source: Federico II University
• Contact: Roberto Berni Canani, Phd
• Email: ritanocerino[@]alice.it
• Is FDA regulated: No
• Health authority: Ethics Commitee of Naples':' "Carlo Romano"
• Study type: Interventional

Clinical Trial Summary

Food allergy (FA), defined as an adverse immune response to food allergens, is among the most frequent allergic disorders in childhood and it has recognized as a major paediatric health problem due to the severity of the reactions and the dramatic increase over the past decades. Cow's milk allergy (CMA) is the most frequent FA in children worldwide, and it has been demonstrated that it could be the first manifestation of the so-called "atopic march", characterized by the occurrence of other allergic disorders in the subsequent years after the onset of CMA. In a previous study, involving children with CMA over a period of 5 years, 40% developed asthma, 21% atopic eczema, and 43% allergic rhinitis. Similar results have been reported in a recent study on Finnish children Intestinal microflora appears to have a crucial role in the development of atopic disorders. Children with atopic diseases have different commensal bacterial groups in the gut compared to non-atopic children, and differences are also found between countries with high and low incidence of atopic diseases. There is currently great interest in manipulating the normal microbiota to accrue health benefits through an approach known as "probiotics." Probiotics are defined as "live microorganisms which when administered in adequate amounts confer a health benefit on the host". The conceptual basis of possible use of probiotics in the prevention and treatment of atopic disorders is well grounded. Lactobacillus GG (LGG) is the most studied probiotic in the prevention and treatment of atopic disorders. Wide and well-designed clinical studies have provided several evidences on the efficacy of LGG as preventive or therapeutic strategy in pediatric atopic disorders. More recently, in vitro studies have provided evidences on the potent immunoregulatory role and on the influence on intestinal microflora composition (toward a more beneficial composition in the prevention and treatment of atopic disorders) elicited by LGG. This view has been further reinforced by recent research showing that LGG is able to improve recovery of intestinal symptoms in infants with CMA-induced allergic colitis.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 180
• Est. completion date: December 2014
• Est. primary completion date: December 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: N/A to 12 Months

Eligibility

Inclusion Criteria:

• infants aged less than 12 months, with a diagnosis of cow's milk allergy

Exclusion Criteria:

• age higher than 12 months,

• concomitant chronic systemic diseases,

• congenital cardiac defects,

• active tuberculosis,

• autoimmune diseases,

• immunodeficiency,

• chronic inflammatory bowel diseases,

• celiac disease,

• cystic fibrosis,

• metabolic diseases,

• malignancy,

• chronic pulmonary diseases,

• malformations of the gastrointestinal tract,

• suspected eosinophilic esophagitis or eosinophilic enterocolitis,

• suspected food-protein-induced enterocolitis syndrome,

• suspected cow's milk proteins-induced anaphylaxis

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

• Atopic Disease
• Cow's Milk Allergy
• Milk Hypersensitivity

Intervention

Dietary Supplement:
• Extensively hydrolyzed casein formula + LGG
Extensively hydrolyzed formula containing Lactobacillus GG

Locations

Country	Name	City	State
Italy	University of Naples Federico II	Naples

Sponsors (1)

Lead Sponsor	Collaborator
Federico II University

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Occurrence of allergic manifestations	Occurrence of allergic manifestations in children with CMA including atopic eczema, allergic urticaria, asthma, allergic rhinitis.Information on social and demographic factors, family and living conditions, and smoking habits will be documented. Unscheduled visit will be made when possible allergic symptoms will appear. Every 12 months sensitization to common dietary and respiratory antigens will be assessed by skin prick tests (SPT) and prick by prick tests.	3 yrs	No
Secondary	Allergic sensitization	Every 12 months sensitization to common dietary and respiratory antigens will be assessed by skin prick tests (SPT) and prick by prick tests.	3 yrs	No